Перспективы применения таргетной химиотерапии деламанидом в схемах лечения больных туберкулезом с множественной/широкой лекарственной устойчивостью возбудителя. Успехи, возможности или неопределенность?


https://doi.org/10.21292/2075-1230-2018-96-11-74-82

Полный текст:


Аннотация

Представлен обзор современных статей, клинических рекомендаций и руководств (гайдлайнов) зарубежных авторов, посвященных проблеме лечения туберкулеза с лекарственной устойчивостью возбудителя, с использованием препарата деламанид. В источниках представлены сведения о высокой эффективности деламанида при его использовании в комбинации с другими противотуберкулезными препаратами для лечения больных МЛУ-туберкулезом органов дыхания – у 74,5% пациентов к завершению 6-месячного курса терапии удалось добиться полного прекращения бактериовыделения.

Об авторах

А. Г. Наумов
ФГБОУ ВО «Приволжский исследовательский медицинский университет» МЗ РФ
Россия
ассистент кафедры фтизиатрии им. И. С. Николаева.
603093, г. Нижний Новгород, ул. Родионова, д. 198.


А. В. Павлунин
ФГБОУ ВО «Приволжский исследовательский медицинский университет» МЗ РФ
Россия
доктор медицинских наук, профессор, заведующий кафедрой фтизиатрии им. И. С. Николаева.
603093, г. Нижний Новгород, ул. Родионова, д. 198.


Список литературы

1. Васильева И. А. и др. Заболеваемость, смертность и распространенность как показатели бремени туберкулеза в регионах ВОЗ, странах мира и в Российской Федерации. Часть 1. Заболеваемость и распространенность туберкулеза // Туб. и болезни легких. – 2017. – Т. 95, № 6. – С. 9-21.

2. Нечаева О. Б. Аналитический обзор ситуации по туберкулезу в России в 2016 году. – М., 2016. – 69 с.

3. Нечаева О. Б. Аналитический обзор основных статистических показателей по туберкулезу в России. – М., 2017. – 4 с.

4. Ahuja S. D., Ashkin D., Avendano M. et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients // PLoS Med. – 2012. – Vol. 9. – Mode of access: https://www.ncbi.nlm.nih.gov/pubmed/22952439. – Date of access: 19.03.2018.

5. Barry P. J., O’Connor T. M. Novel agents in the management of Mycobacterium tuberculosis disease // Curr. Med. Chemistry. – 2007. – Vol. 14, № 18. – P. 2000-2008.

6. Bonnet M., Bastard M., du Cros P. et al. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR TB cohort study // Intern. J. Tub. Lung Dis.: the official journal of the International Union against Tuberculosis and Lung Disease. – 2016. – Vol. 20, № 2. – P. 177-186.

7. Borisov S. E., Dheda K., Enwerem M. et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study // Eur. Respir. J. – 2017. – Vol. 49, № 5. – Mode of access: https://www.ncbi.nlm.nih.gov/pubmed/28529205. – Date of access: 01.04.2018.

8. Brigden G., Hewison C., Varaine F. New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid // Infect. Drug Resist. – 2015. – № 8. – P. 367-378.

9. Budha N. R. A Pharmacokinetics and pharmacodynamics (PK/PD) guided approach to lead optimization of nitrofuranylamide anti-tuberculosis agents // Theses and Dissertations (ETD). – 2009. – Vol. 5. – P. 30-33.

10. Byun J. H., Park J. A., Kang H. R. et al. Comparison of effectiveness between delamanid and bedaquiline among patients with multidrug-resistant tuberculosis: a Markov model simulation study // Clin. Drug Investig. – 2016. – Vol. 36, № 11. – P. 957-968.

11. Conradie F., Meintjes G., Hughes J. et al. Clinical Access to bedaquiline programme of drug-resistant tuberculosis // South African Med. J. – 2014. – Vol. 104, № 3. – P. 164-166.

12. Cox H. S., Furin J. J., Mitnick C. D. et al. The need to accelerate access to new drugs for multidrug-resistant tuberculosis // Bulletin of the World Health Organization. – 2015. – Vol. 93, № 7. – P. 491-497.

13. Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells // Natur. Rev. Microbiol. – 2014. – № 12. – P. 159-167.

14. Dedicoat M. Using bedaquiline and delamanid in combination and safety // Intern. J. Tuberc. Lung Dis: the official journal of the International Union against Tuberculosis and Lung Disease. – 2016. – Vol. 20, № 10. – P. 1282.

15. Delamanid [Electronic resource]. – Mode of access: http://www.chemspider.com/Chemical-Structure.4981055.html. – Date of access: 10.04.2018.

16. Diacon A. H., Dawson R., Hanekom M. et al. Early bacterial activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients // Internat. J. Tuberc. Lung Dis.: the official journal of the International Union against Tuberculosis and Lung Disease. – 2011. – Vol. 15, № 7. – P. 949-954.

17. Diacon A. H., Pym A., Grobusch M. P. et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline // New Engl. J. Med. – 2014. – Vol. 371, № 8. – P. 723-732.

18. Diacon A.H., von Groote-Bidlingmaier F., Delamanid P. R. D. A new 6-nitro-2,3-dihydroimidazo[2,1-b] oxazole for the management of tuberculosis resistant to at least isoniazid and rifampicin // Expert Opinion on Orphan Drugs. – 2014. – Vol. 2, № 1. – P. 87-94.

19. Diel R., Hittel N., Schaberg T. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba to background regimens in Germany // Respir. Med. – 2015. – Vol. 109, № 5. – P. 632-641.

20. Diel R., Nienhaus A., Lampenius N. et al. Cost of multi drug resistance tuberculosis in Germany // Respir. Med. – 2014. – Vol. 108, № 11. – P. 1677-1687.

21. European Medicines Agency. Assessment Report: Deltyba. London: European Medicines Agency. – 2013. – 140 p.

22. European Medicines Agency. Summary of product characteristics. Deltyba. Otsuka Novel Products GmbH. European Medicines Agency. – 2014. – P. 2-29.

23. Falzon D., Nhat N. L., Ernesto J., Karin W. The global response to rifampicin-resistant tuberculosis: current situation and recent trends // Europ. Respir. J. – 2016. – Vol. 48, № 60. – P. 1903.

24. Falzon D., Schunemann H. J., Harausz E. et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update // Europ. Respir. J. – 2017. – Vol. 49, № 3. – Mode of access: https://www.ncbi.nlm.nih.gov/pubmed/28331043. – Date of access: 01.03.2018.

25. Ferlazzo G. et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study // Lancet Infect. Dis. – 2018. – P. 1-9. – Mode of access: https://www.ncbi.nlm.nih.gov/pubmed/29452942. – Date of access: 19.03.2018.

26. Gler M. T., Skripconoka V., Sanchez-Garavito E. et al. Delamanid for multidrug-resistant pulmonary tuberculosis // New Engl. J. Med. – 2012. – Vol. 366, № 23. – P. 2151-2160.

27. Global tuberculosis report 2017. – Geneva: World Health Organization, 2017. – 147 p.

28. Gruber K. Access sought to tuberculosis drug from nutraceutical company // Nature medicine. – 2015. – Vol. 21, № 2. – P. 103.

29. Guglielmetti L., Du D. L., Jachym M. et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort // Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. – 2015. – Vol. 60, № 2. – P. 188-194.

30. Gupta R., Geiter L. J., Wells C. D. et al. Delamanid for extensively drug-resistant tuberculosis // New Engl. J. Med. – 2015. – Vol. 373, № 3. – P. 291-292.

31. Harausz E. P., Garcia-Prats A., Seddon J. A. et al. New drugs, repurposed drugs, and novel regimens for children with multidrug-resistant tuberculosis: practice-based recommendations // Am. J. Respir. Crit. Care Med. – 2017. – Vol. 195, № 10. – Mode of access: https://www.atsjournals.org/doi/abs/10.1164/rccm.201606-1227CI?journalCode=ajrccm. – Date of access: 01.03.2018.

32. Horsburgh C. R. Jr., Haxaire-Theeuwes M., Lienhardt C. et al. Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis // The international journal of tuberculosis and lung disease: the official journal of the International Union against. – 2013. – Vol. 17, № 2. – P. 146-152.

33. Lachatre M., Rioux C., Du D. L. et al. Bedaquiline plus delamanid for XDR tuberculosis // Lancet. Infect. Dis. – 2016. – Vol. 16, № 3. – P. 294.

34. Lewis M. J. et al. The role of delamanid in the treatment of drug-resistant tuberculosis // Therap. Clin. Risk Management. – 2015. – Vol. 11. – P. 779-791.

35. Lienhardt C., Nahid P., Rich M. L. et al. Target regimen profiles for treatment of tuberculosis: A WHO document // Europ. Respir. J. – 2017. – Vol. 49. – Mode of access: http://erj.ersjournals.com/content/49/1/1602352. – Date of access: 01.03.2018.

36. Ma Z., Lienhardt C., McIlleron H. et al. Global tuberculosis drug development pipeline: the need and the reality // Lancet. – 2010. – Vol. 375, № 9731. – P. 2100-2109.

37. Matsumoto M., Hashizume H., Tomishige T. et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice // PLoS Med. – 2006. – Vol. 9, № 11 – P. 2131-2144.

38. Matteelli A., D’Ambrosio L., Centis R. Compassionate and optimum use of new tuberculosis drugs // Lancet. Infect Dis. – 2015. – Vol. 15, № 10. – P. 1131-1132.

39. Migliori G. B. et al. Combined use of delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis: a systematic review // Internat. J. Molecul. Sci. – 2017. – Vol. 18, № 2. – Mode of access: https://www.ncbi.nlm.nih.gov/pubmed/28178199. – Date of access: 01.04.2018.

40. Migliori G. B., Eker B., Richardson M. D. et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis // Eur. Respir. J. – 2009. – Vol. 34, № 2. – P. 387-393.

41. Millikaarjun S., Wells C., Petersen C. Delamanid coadministred with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects // Antimicrob. Agents Chemother. – 2016. – Vol. 60, № 10. –P. 5976-5985.

42. Mukherjee T., Boshoff H. Nitroimidazoles for the treatment of TB: past, present and future // Future Med. Chemistry. – 2011. – Vol. 3, № 11. – P. 1427-1454.

43. Mullerpattan B. J., Udwadia Z. F. Bedaquiline and Delamanid: Sharing the Indian Experience // Actrocyte. – 2017. – Vol. 4. – P. 108-110.

44. Ndjeka N., Conradie F., Schippel K. et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis // Intern. J. Tub. Lung Dis.: the official journal of the International Union against Tuberculosis and Lung Disease. – 2015. – Vol. 19, № 8. – P. 979-985.

45. Nuermberger E. L., Spigelman M. K., Yew W. W. Current development and future prospects in chemotherapy of tuberculosis // Respirology. – 2010. – Vol. 15, № 5. – P. 764-778.

46. Olaru I. D., von Groote-Bidlingmaier F., Heyckendorf J., Yew W. W. et al. Novel drugs against tuberculosis: a clinician’s perspective // Europ. Resp. J. – 2015. – Vol. 45, № 4. – P. 1119-1131.

47. Pontali E., Sotgiu G., D’Ambrosio L. et al. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence // Eur. Respir. J. – 2016. – Vol. 47, № 2. – P. 394-402.

48. Rustomjee R., Zumla A. Delamanid expanded access novel treatment of drug resistant tuberculosis // Infect. Drug Resist. – 2015. – Vol. 8. – P. 359-366.

49. Ryan N. J., Lo J. H. Delamanid: first global approval // Drugs. ‒ 2014. – Vol. 74, № 9. – P. 1041-1045.

50. Saliu O. Y., Crismale C. et al. Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis // J. Antimicrob. Chemother. – 2007. – Vol. 60, № 5. – P. 994-998.

51. Sasahara K., Shimokawa Y., Hirao Y. et al. Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo // Drug Metabolism and Disposition: the biological fate of chemicals. – 2015. – Vol. 43, № 8. – P. 1267-1276.

52. Sasaki H., Haraguchi Y., Itotani M. et al. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b] oxazoles // J. Med. Chemistry. – 2006. – Vol. 29, № 26. – P. 7854-7860.

53. Shan N. S. et al. Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa // Emerg. Infect. Dis. – 2011. ‒ Vol. 17, № 3. – P. 510-513.

54. Shimokawa Y., Sasahara K., Koyama N. et al. Metabolic mechanism of delamanid, a new anti-tuberculosis drug, in human plasma // Drug Metabol. Disposit: the biological fate of chemicals. – 2015. – Vol. 43, № 8. – P. 1277-1283.

55. Shimokawa Y., Sasahara K., Yoda N. et al. Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro // Biological & pharmaceutical bulletin. – 2014. – Vol. 37, № 11. – P. 1727-1735.

56. Singla R. Drug-resistant tuberculosis: key strategies for a recalcitrant disease // Actrocyte. – 2017. – Vol. 4, №1. – P. 53-62.

57. Skripconoka V., Danilovits M., Pehme L. et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis // Europ. Respir. J. – 2013. – Vol. 41, № 6. – P. 1393-1400.

58. Sloan D. J., Lewis J. M. Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings // Transact. Royal Society Trop Med. Hygiene. – 2016. – Vol. 110, № 3. – P. 163-172.

59. Sotgiu G., Pontali E., Centis R. et al. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis // Expert Rev. Anti-Infective Therapy. – 2015. – Vol. 13, № 3. – P. 305-315.

60. Sotgiu G., Pontali E., Centis R. et al. New anti-tuberculosis drugs for special populations: A difficult-to-address issue // Europ. Respir. J. – 2016. – Vol. 48, № 3. – P. 957-958.

61. Sotgiu G., Tiberi S., D’Ambrosio L. et al. Faster for less, the new “Shorter” regimen for multidrug-resistant tuberculosis // Eur. Respir. J. – 2016. – Vol. 48, № 5. – P. 1503-1507.

62. Stinson K. et al. MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration // Antimicrob. Agents Chemother. – 2016. – Vol. 60, № 6. – P. 3316-3322.

63. Stover C. K., Warrener P., VanDevanter D. R. et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis // Nature. – 2000. – Vol. 405, № 6789. – P. 962-966.

64. Szumowski D. J. et al. Profile of delamanid for the treatment of multidrug-resistant tuberculosis // Drug Design, Devel. Therapy. – 2015. – Vol. 9. – P. 677-682.

65. Tadolini M., Lingsang R. D., Tiberi S. et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline // Europ. Respir. J. – 2016. – Vol. 48, № 3. – P. 935-938.

66. The selection and use of essential medicine report. – Geneva: World Health Organization, 2015. – 546 p.

67. The use of Bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. – Geneva: World Health Organization, 2013. – 57 p.

68. The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance. – Geneva: World Health Organization, 2014. – 65 p.

69. The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance. – Geneva: World Health Organization, 2016. – 48 p.

70. Tiberi S., D’Ambrosio L., de Lorenzo S. et al. Tuberculosis elimination, patients’ lives and rational use of new drugs: revisited // Eur. Respir. J. – 2016. – Vol. 47, № 2. – P. 664-667.

71. Tiberi S., Scardigli A., Centis R. et al. Classifying new anti-TB drugs: rationale and future perspectives // Intern. J. Infect. Dis. – 2017. – Vol. 56. – P. 181-184.

72. Treatment guidelines for drug-resistant tuberculosis 2016 Update. – Geneva, Switzerland: World Health Organization, 2016. – 56 p.

73. Udwadia Z. F. Totally drug-resistant tuberculosis in India: who let the djinn out? // Respirology. – 2012. – Vol. 17, № 5. – P. 741-742.

74. Vassell A. Cost-effectiveness of introducing bedaquiline in MDR-TB regimens ‒ an exploratory analysis. – Geneva: World Health Organization, 2013. – 30 p.

75. Velayati A. A. et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran // Chest. – 2009. – Vol. 136, № 2. – P. 420-425.

76. Wallis R. S. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine // Eur. Respir. J. – 2016. – Vol. 48, № 5. – P. 1526-1527.

77. Wirth D. et al. Cost-effectiveness of adding novel or group 5 inerventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany // BMC Health Services Research. – 2017. – Vol. 17, № 182. – P. 1-11.

78. Wolfson L. J., Gibbert J., Wirth D., Diel R. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for multidrug-resistant/extensively drug-resistant tuberculosis in Germany // Eur. Respir. J. – 2015. – Vol. 46, № 6. – P. 1826-1829.

79. Zhang Q., Liu Y., Tang S. et al. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China // Cell Biochem. Biophys. – 2013. – Vol. 67, № 3. – P. 957-963.


Дополнительные файлы

Для цитирования: Наумов А.Г., Павлунин А.В. Перспективы применения таргетной химиотерапии деламанидом в схемах лечения больных туберкулезом с множественной/широкой лекарственной устойчивостью возбудителя. Успехи, возможности или неопределенность? Туберкулез и болезни легких. 2018;96(11):74-82. https://doi.org/10.21292/2075-1230-2018-96-11-74-82

For citation: Naumov A.G., Pavlunin A.V. Perspectives of targeted chemotherapy with delamanid in the treatment regimens of those with multiple/extensive drug resistant tuberculosis. A success, chance or uncertainty? Tuberculosis and Lung Diseases. 2018;96(11):74-82. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-11-74-82

Просмотров: 76

Обратные ссылки

  • Обратные ссылки не определены.


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2075-1230 (Print)
ISSN 2542-1506 (Online)